Rocklatan®
netarsudil 0.02% / latanoprost 0.005% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) once daily in the evening, not to exceed once daily
Nearly a third reach a 40% or greater IOP reduction, versus under 10% on either component alone.
Contraindications
None listed on the FDA label.
0.02%/0.005% ophthalmic solution (netarsudil 0.2 mg/mL, latanoprost 0.05 mg/mL), 2.5 mL fill in a 4 mL bottle
Fixed combination of netarsudil, a Rho kinase inhibitor, and latanoprost, a prostaglandin F2alpha analogue; each component decreases elevated IOP, and the combination is believed to reduce IOP by increasing the outflow of aqueous humor. A review of the fixed-dose combination reports that it reduces IOP by enhancing aqueous outflow through both the trabecular pathways (Rho kinase inhibition) and uveoscleral pathways (prostaglandin analogue).
Warnings & Precautions
- Epithelial corneal edema: Netarsudil component; epithelial corneal edema, described as honeycomb or bullous, has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures that could affect corneal endothelial function. It typically resolves upon discontinuation. Advise patients to notify their physician if they experience eye pain or decreased vision.
- Iris and periorbital pigmentation: Latanoprost component; pigmentation of the iris, periorbital tissue (eyelid) and eyelashes is expected to increase as long as latanoprost is administered; typically the brown pigmentation around the pupil spreads concentrically. Iris pigmentation is likely to be permanent, while periorbital and eyelash changes have been reported to be reversible in some patients. Nevi and freckles of the iris appear unaffected; treatment may continue with regular examination.
- Eyelash changes: Latanoprost may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth; usually reversible upon discontinuation.
- Intraocular inflammation: Caution with a history of iritis or uveitis, and generally not for use with active intraocular inflammation, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported with latanoprost; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Herpetic keratitis: Reactivation of herpes simplex keratitis has been reported with latanoprost; caution with a history of it and avoid in active herpes simplex keratitis, which may be exacerbated.
- Paradoxical elevations in IOP: Combining two or more prostaglandins or prostaglandin analogs is not recommended, and dosing more than once daily may decrease the IOP lowering effect or cause paradoxical IOP elevation.
- Precipitation: In vitro studies have shown that precipitation can occur when eye drops containing thimerosal are mixed with ROCKLATAN; if such drugs are used, administer them at least 5 minutes apart.
- Bacterial keratitis: Reported with contaminated multiple-dose containers, in most cases in eyes with concurrent corneal disease or a disrupted epithelial surface.
- Use with contact lenses: Benzalkonium chloride 0.02% may be absorbed by soft lenses; remove before instillation and reinsert after 15 minutes.
Common Side Effects
Conjunctival hyperemia was the most common ocular adverse reaction (59%), and 5% of patients discontinued therapy for it. Other common ocular reactions were instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%); eye pruritus, reduced visual acuity, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5% to 8% of patients. Reactions reported with the individual components include instillation site erythema and corneal staining (netarsudil) and foreign body sensation, punctate keratitis, increased iris pigmentation, dry eye, eye pain, photophobia, upper respiratory tract infection, myalgia, and rash or allergic reactions (latanoprost). Postmarketing, epithelial corneal edema has been reported in some patients with pre-existing corneal stromal edema or ocular procedures that could affect corneal endothelial function.
Pregnancy: No adequate and well-controlled studies of the combination or either component in pregnant women; use only if the potential benefit justifies the potential risk to the fetus. Latanoprost caused embryofetal lethality in rabbits at approximately 80 times the recommended human ophthalmic dose (no viable fetuses in 4 of 16 pregnant rabbits) but not at approximately 15 times, while IV netarsudil in pregnant rats and rabbits produced no adverse embryofetal effects at clinically relevant systemic exposures.
Lactation: No data on the presence of either component in human milk, effects on the breastfed infant, or effects on milk production; systemic exposure to netarsudil after ocular dosing is low.
Safety and effectiveness in pediatric patients not established.